Alnylam identifies gene to lower abdominal fat and decrease cardiovascular risk
Pharmaceutical Technology
AUGUST 11, 2022
Alnylam Pharmaceuticals and collaborators have identified rare mutations in the INHBE gene that is expressed in the liver, related to a lower waist-to-hip ratio for body mass index (BMI), which is often used as an indicator of abdominal fat and is correlated with the risk of type 2 diabetes (T2D) and coronary heart disease.
130 
Let's personalize your content